RecruitingPhase 4NCT06269432

Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Ischemic STROKE（PATH-STROKE）

Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Ischemic STROKE

Sponsor

Sichuan Provincial People's Hospital

Enrollment

1,020 participants

Start Date

Jan 1, 2023

Study Type

INTERVENTIONAL

Conditions

Ischemic Stroke Antiplatelet Drug

Summary

1. Main objective: To explore the efficacy of precise antiplatelet therapy guided by platelet aggregation function in reducing the incidence of 30 day platelet hyperresponsiveness in patients with non-cardiogenic ischemic stroke. 2. Secondary objective: To explore the efficacy and safety of antiplatelet therapy in patients with non-cardiogenic ischemic stroke under the guidance of platelet aggregation function.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria6

Aged from 18 to 80 years;
Diagnosed with non-cardiogenic ischemic stroke according to WHO criteria, confirmed by cranial CT or MRI to exclude hemorrhagic stroke.;
First stroke onset ≥ 1 month and ≤ 3 months;
mRS Score <=2 points;
Undergoing antiplatelet therapy with 100mg aspirin daily for at least 8 days;
Informed consent signed by the patient or their family member.

Exclusion Criteria5

History of recurrent stroke.
History of gastrointestinal bleeding, intracranial hemorrhage, or other bleeding disorders.
Contraindications or intolerance to antiplatelet therapy medications.
Severe cardiac, pulmonary, hepatic, or renal insufficiency, or presence of severe comorbid conditions (e.g., end-stage malignant tumors, severe single/multiple organ failure).
Poor compliance, inability to cooperate with study requirements.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPrecision Antiplatelet Therapy Trial Group

Use SPCM method to detect platelet aggregation function in patients, adjust antiplatelet drugs based on the test results, and receive precise antiplatelet treatment for 12 months. Non resistant patients with aspirin will continue to receive aspirin 100mg qd; Patients with aspirin resistance were given clopidogrel 75mg qd; Clopidogrel resistant patients were given ticagrelor 90mg bid.

DRUGTraditional Antiplatelet Therapy Control Group

No adjustment of antiplatelet medication is required, and routine treatment with aspirin 100mg qd is given for 12 months.